MMP19 and diabetic kidney disease: RASi, SGLT2i, and finerenone can serve as the three main pillars for treating DKD, forming multiple combination therapy protocols for DKD [24,25], while GLP-1RA may be a potential fourth pillar for treating DKD [26].